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The sympathetic nervous system has been implicated in pain associated with painful diabetic neuropathy. However, therapeutic
intervention targeted at the sympathetic nervous system has not been established. We thus tested the hypothesis that sympathetic
nerve blocks signiﬁcantly reduce pain in a patient with painful diabetic neuropathy who has failed multiple pharmacological
treatments. The diagnosis of small ﬁber sensory neuropathy was based on clinical presentations and conﬁrmed by skin biopsies.
A series of 9 lumbar sympathetic blocks over a 26-month period provided sustained pain relief in his legs. Additional thoracic
paravertebral blocks further provided control of the pain in the trunk which can occasionally be seen in severe diabetic neuropathy
cases, consequent to extensive involvement of the intercostal nerves. These blocks provided sustained and signiﬁcant pain relief
and improvement of quality of life over a period of more than two years. We thus provided the ﬁrst clinical evidence supporting
the notion that sympathetic nervous system plays a critical role in painful diabetic neuropathy and sympathetic blocks can be an
eﬀective management modality of painful diabetic neuropathy. We concluded that the sympathetic nervous system is a valuable
therapeutic target of pharmacological and interventional modalities of treatments in painful diabetic neuropathy patients.
1.Introduction
Diabetic polyneuropathy is one of the most common forms
of peripheral neuropathy. It aﬄicts patients of both type 1
and type 2 diabetes with an increased prevalence as the dis-
ease progresses [1–3]. Up to 50% of all diabetics with long-
duration diabetes have polyneuropathy which is a major
causeofmorbidityandisassociatedwithincreasedmortality.
Up to 26% of diabetics develop painful diabetic neuropathy
(PDN) with debilitating eﬀects on quality of life [4–6]. Man-
agement of PDN remains an enormous challenge to both the
patients and the clinicians as we have recently reviewed [7].
The current strategy includes mandatory glycemic control
and pain control by pharmacological treatment with local
anesthetic patches, anticonvulsants, tricyclic antidepressants,
selective serotonin and noradrenalin reuptake inhibitors,
and/or opioids. Spinal cord stimulation has been tested in
a few studies involving a small number of highly selected
patients who failed to respond to conservative treatments,
with some degree of positive eﬀects [8, 9]. However, the pain
control of diabetic neuropathy remains a daunting challenge
and the overall outcomes of the current management of
diabetic neuropathy are not satisfactory.
Although diabetic polyneuropathy is clinically known
for over a century, the pathophysiological mechanisms
were only recently better understood. It is recognized
that the microvascular dysfunction, secondary to chronic
hyperglycemia and dyslipidemia, is a common pathophys-
iological basis of polyneuropathy and other microvascular
complications with diabetes. There is also evidence that the
sympathetic nervous system may play an important role in
painful diabetic neuropathy. Circulating norepinephrine is
higher in painful than painless diabetic neuropathy, and its
concentration is correlated with the severity of neuropathic
pain [10]. Thus, painful diabetic neuropathy is suggested to





Figure 1: PGP9.5 immunostaining of skin biopsies at the distal leg. The patient with painful diabetic neuropathy (b) showed reduced
intraepidermal nerve ﬁbers (red arrow), in comparison to a normal subject (a) who showed many intraepidermal nerve ﬁbers (red arrows).
sympathetic ﬁbers that may contribute to pain. Damaged
peripheral nerves became hyperexcitable through abnormal
electrical connections that may have resulted in ephaptic
transmission or “crosstalking” between sensory and sympa-
thetic nerve ﬁbers [11, 12]. Indeed, norepinephrine excited
the ongoing ephaptic activity in damaged peripheral nerves
through activation of alpha receptors [11]. Furthermore,
patients with PDN had impaired sympathetically mediated
vasoconstriction, contributing to inappropriate local blood
ﬂow regulation in these patients [13].
Based on these observations, we hypothesized that
sympathetic nerve blocks may reduce pain associated with
diabetic neuropathy by reducing sympathetic outﬂow and
improving circulation. We tested this hypothesis in a patient
with severe PDN refractory to multiple pain medications by
treating him with lumbar and thoracic sympathetic blocks.
The diagnosis of small ﬁber sensory neuropathy was based
on clinical presentations and conﬁrmed by skin biopsies.
A series of 9 lumbar sympathetic blocks over a 26-month
period provided sustained pain relief in his legs. Additional
thoracic paravertebral blocks further provided control of his
pain in the trunk from dermatomes T6 to L1, consequent
to extensive involvement of PDN. These blocks signiﬁcantly
improved his quality of life over a period of more than two
years.
2.CaseReport
The patient is a 37-year-old right-handed Caucasian man
who was in his usual state of health until December 2006
when he started to notice that his feet were cold, numb,
and had a tingling sensation (described as pins and needles)
from the ankles down. In a few weeks, the tingling sensation
progressed up to the knees which remained stable for the
next three months. In April 2007, he also noted the tingling
sensation in the arms.
At time of his presentation to our pain clinic and neu-
rology clinic in October 2007, he reported diﬀuse constant
tingling sensation, mostly involving his arms, legs, and face,
which was accompanied by sharp pains, mostly in the feet
and distal legs. The pain was rated on average as an 8 on a
numerical rating scale (NRS) (0 is no pain and 10 is most
severe pain imaginable). He also reported episodic lower
extremity allodynia to light touch and burning dysesthesia
in his trunk and hands. These symptoms kept him up
at night and disturbed his sleep. He began to experience
symptoms of depression secondary to the relentless pain
condition. He denies weakness. Physical examination at the
time of presentation was signiﬁcant for decreased light touch
sensation and hyperalgesia to pinprick in a stocking-glove
distribution. Motor strength, proprioception, and tendon
r e ﬂ e x e sw e r ew e l lp r e s e r v e d .
A nerve conduction study and electromyography was
normal showing no evidence of a large ﬁber peripheral
neuropathy or radiculopathy. We further conducted skin
biopsies at the distal leg (DL), distal thigh (DT), and proxi-
malthigh(PT)intheClevelandClinicCutaneousNerveLab-
oratory and carried out intraepidermal nerve ﬁber density
(IENFD) analysis as previously described [14, 15]. Intraepi-
dermal nerve ﬁber density was signiﬁcantly reduced at the
distal leg as compared to normal control (Figure 1), which
indicates a distal small ﬁber sensory neuropathy. The neu-
ropathy etiology evaluation was signiﬁcant for diabetes mel-
litus as revealed by oral glucose tolerance test with a 2-hour
glucose level being 220mg/dL. ESR, ANA, ENA, rheumatoid
factor, ACE level, ANCAs, TSH, free T4, serum and urine
immunoﬁxation, folic acid, vitamin B12, RPR, Lyme serol-
ogy, and heavy metal screen were all unremarkable.
He was diagnosed with painful diabetic small ﬁber
sensory neuropathy and started on Glucophage. In terms
of his neuropathic pain control, however, he had failed to
respond to multiple pain medications, including Topira-
mate, Oxcarbazepine, Duloxetine, Amitriptyline, Darvocet,
Tramadol, and Lidocaine transdermal patches. Gabapentin
only oﬀered minimal pain relief. Given the unsatisfactory
outcomes of conservative treatment, we decided to try
a lumbar sympathetic block for his pain and allodynia






























































Figure 2: Sympathetic block-induced changes in temperature and
NRS pain scores. (a) The peak temperatures, monitored at the
plantar surface of the toes with an electronics device, increased
signiﬁcantly in both sides after bilateral lumbar sympathetic blocks
(post)comparedtothebaselinevaluestakenbeforetheblocks(pre).
(b)TheNRSpainscores,evaluatedinthepreprocedureroombefore
the blocks (pre) and in the recovery room after the block (post),
decreased signiﬁcantly after each lumbar sympathetic block.
bilateral lumbar sympathetic block at the level of L3 under
ﬂuoroscopic guidance and injected a mixture of 12mL of
1% Lidocaine and 20mg Triamcinolone on each side. The
temperatures, monitored in the plantar surface of the big
toes (LS 14000 Temperature Monitor and Skin Temperature
Probe,NovaMed,NY,USA),increasedsigniﬁcantly,andNRS
pain scores decreased substantially after the procedure as
shown in Table 1 (initial block) and Figure 2.
Athis2-monthfollowup,thepatientreported“excellent”
relief of his foot pain bilaterally for over 6 weeks, but became
morecognizantofhisthoracicandhandpain.Adecisionwas
made to proceed with a repeat lumbar sympathetic block to
further enhance the pain relief. Subsequent temperature and
pain score changes were again noted as shown in Table 1 (2
months) and Figure 2. Management of his thoracic pain was
further considered at the following oﬃce visit. At a follow-
up visit 4 weeks later, the patient again reported “signiﬁcant,
sustained” relief of his bilateral foot pain. He felt “dramatic”
improvement of the “coldness and tingling pain” with the
ﬁrst injection with sustained relief that was further enhanced
with the second procedure.
At this point, his chief complaint became the “hyper-
sensitive, pins and needles, burning” thoracic and abdom-
inal pain that was described as occupying a discrete
antero-/posteroarea of his thorax, roughly covering the T6
to the L1 dermatomes. Physical examination, as previously
described, was signiﬁcant only for bilateral lower extremity
stocking-distribution decrease in sensation to light touch
and pinprick. He returned 2 weeks later for a T8 bilateral
paravertebralsympatheticnerveblock,whichwasperformed
in the classic fashion, under ﬂuoroscopic guidance. A
solution of 1% Lidocaine 10mL and 20mg Triamcinolone
was injected on each side. The patient was maintained on the
same doses of Gabapentin and Tramadol. Upon his return
to the clinic 4 weeks later, he reported “70%” relief of his
thoracic pain following his T8 paravertebral block. By this
point, his bilateral foot pain was 5 on the NRS three months
following his second lumbar sympathetic block; therefore,
a third bilateral lumbar sympathetic block was performed
(Table 1, 4 months). Pain medications remained the same,
and the patient was followed up in three months.
Over the next two years, the patient continued to have
lower extremity neuropathic pain as described above with
good, sustained pain relief after each of subsequent lumbar
sympathetic blocks. The intervals of each block are shown
in Table 1 (Figure 2) with the corresponding temperature
changes and the NRS pre- and postblock pain scores. He
additionally underwent two thoracic paravertebral blocks
at the T6 level in April and May of 2010 with good relief
following each procedure. The remainder of his clinical
course was uneventful.
3. Discussion
We observed that lumbar and thoracic sympathetic nerve
blocks signiﬁcantly improved the circulations and reduced
neuropathic pain in this patient with diabetic small ﬁber
sensory neuropathy. The analgesic eﬀects are reproducible
upon repeated blocks and are long-lasting (sustained 2–
4 months after each block). These observations support
the notion that the sympathetic nervous system plays a
critical role in the pathophysiological mechanisms of painful
diabetic polyneuropathy. This case report thus provides the
ﬁrst clinical evidence supporting the notion that the pain in
diabetic neuropathy may be sympathetically mediated to a
signiﬁcant extent that has not been recognized previously.
Given the sustained pain relief after each sympathetic
block, the sympathetic nervous system may prove to be
an important therapeutic target of pharmacological and
interventional treatments for painful diabetic neuropathy.
Painful diabetic neuropathy is a relatively common med-
ical condition, which can predominantly aﬀect small sensory
nerve ﬁbers [16]. Glucose dysmetabolism, including diabetes
and prediabetes, is present in about 1/3 of patients with4 Case Reports in Anesthesiology
Table 1: Sympathetic block-induced changes in temperature and NRS pain score.
Number of blocks (months after initial block)
Temperature NRS
Right toe Left toe
Pre Post
Pre Post Pre Post
1 Initial 20.2 33.0 19.7 22.6 5 3
2 (2) 25.3 33.4 24.5 33.2 6 2
3 (4) 24.8 32.6 25.4 34.2 5 1
4 (8) 25.9 34.8 25.2 33.9 3 0
5 (9) 29.2 33.4 25.7 32.7 2 1
6 (13) 24.9 26.3 23.7 19.4 5 4
7 (19) 22.5 33.7 21.5 33.2 5 2
8 (22) 20.2 28.7 20.6 31.3 5 3
9 (26) 28.5 33.0 22.2 33.0 6 2
Average 24.6 32.1 23.2 30.4 4.7 2
painful sensory neuropathy and nearly 50% of otherwise
idiopathic small ﬁber neuropathy [17–20]. Neuropathic pain
can be the presenting symptom of diabetes, as seen in this
patient.Itisoneofthemostdistressingsymptomsofdiabetic
polyneuropathy and the main reason for seeking medical
attention. Typical of painful diabetic neuropathy suﬀerers,
this patient experienced a progressive buildup of unpleasant
sensorysymptomsthatincludetinglingor“pinsandneedles”
(paresthesia),and/orpaincharacteristicofburning,shooting
(like “electric shock” down the legs), lancinating (stabbing
or knifelike), and deep aching quality. The patient also
developed allodynia and hyperalgesia. Furthermore, the
patient experienced pain extended from the lower limbs
to the upper limbs and trunk and face, as sometimes
seen in advanced cases. Consequently, the patient suﬀered
disturbed sleep and depressive mood after multiple failures
to pharmacological treatments.
The patient’s neuropathy is consistent with small ﬁber
sensory neuropathy based on his clinical features and skin
biopsy ﬁndings. Additionally, the patient presented with
thoracic and abdominal pain in a dermatomal distribution
from T6 to L1 bilaterally. This form of pain can be seen in
diabetic peripheral neuropathy although it is not very com-
mon[21,22].Becausethepaininhisfeetandtrunkwasmost
debilitating, we targeted these areas by performing lumbar
and thoracic sympathetic blocks. While lumbar sympathetic
blocks have been widely used in treating patients with
chronic pain conditions in the lower limbs such as complex
regional pain syndromes [23–25], paravertebral blocks have
predominantly been used for surgical and acute pain man-
agement [26]. We utilized the combination of the two blocks
and successfully maintained control of the pain in both his
legs and trunk for more than 2 years. The novel application
of both techniques may thus represent a valuable addition to
the armamentarium of interventional pain management.
Although the mechanism of how a mixture of a local
anesthetic and a steroid medication can produce long-lasting
pain relief is not completely understood as in the case
of epidural steroid injections for radicular pain [27], it
has been shown that steroids can block nociceptive input.
Corticosteroids suppress discharges in chronic neuromas
and prevent ectopic discharge in experimental neuromas,
likely through a direct action on cell membrane [28].
The application of methylprednisolone has been shown
to block C-ﬁbers but not Aβ ﬁbers [29]. Damaged nerve
ﬁbers often have high accumulation of expressed sodium
channels that are particularly sensitive to local anesthetics
such as Lidocaine [30]. Therefore, the sympathetic blocks
with local anesthetics and steroids may provide pain relief
through similar pharmacological actions on nociceptive
ﬁbers. Alternatively, the blocks may reduce sympathetic
outﬂowandcirculatingnorepinephrine,therebydiminishing
alpha receptor stimulation of injured peripheral nerve ﬁbers
[11]. A third explanation for the pain relief may be due to a
sympathectomy-induced improvement in microvascular cir-
culationasindicatedbythedramaticincreaseintemperature
of the toes after the blocks (Figure 2), relieving ischemia
of nociceptors. It has been recognized that, in addition to
a direct toxic eﬀect of glucose on nerve cells, the damage
of the nerve structures is accompanied by a microvascular
dysfunction, which damages the vasa nervorum. The latter
is secondary to the oxidative stress caused by hyperglycemia
and other metabolic/homeostatic disorders. This is consis-
tent with the fact that neuropathy and neuropathic pain
occur more often in patients whose diabetes is chronically
poorly controlled and who also have other cardiovascular
risk factors such as hypertension and hyperlipidemia.
While recognizing the limitations of a case study, the
ﬁndings are evidently intriguing and justify further large-
scale studies. Given the ineﬃciency of current treatment
options [7, 31], search for new therapeutic modalities is par-
ticularly needed. Interventions targeting at the sympathetic
nervous system and its receptors are likely to represent a
novel direction of eﬀective therapy.
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